SLC5A2 and kidney disorder: A meta-analysis of three studies showed that sodium-glucose cotransporter 2 (SGLT2) inhibitors reduced major adverse CV events by 11% in patients with T2DM and atherosclerotic CVD and reduced the risk of CV death or hospitalization for HF by 23% and the risk of renal disease progression by 45% among patients with T2DM [53].